Intraventricular thrombus progression due to poor compliance with anticoagulant treatment in a patient with hypereosinophilic and antiphospholipid syndromes

Hypereosinophilic syndrome is an uncommon disorder defined as persistent eosinophilia (absolute eosinophil count >1500/μl) associated with single or multiple organ dysfunction, where other causes of hypereosinophilia have been excluded. Cardiac involvement occurs in more than 50% of cases and is a major cause of morbidity and mortality in this patient group.\(^1\)\(^-\)\(^3\) The outcome depends on the development of endocardial fibrosis and related complications; therefore, early diagnosis and proper medical treatment are crucial to prevent disease progression.

A 63-year-old man was referred to our department due to exacerbation of heart failure symptoms and atypical chest pain. Six months earlier he was diagnosed with hypereosinophilic syndrome and antiphospholipid syndrome involving the heart and leading to endocardial fibrosis and apical thrombus formation in the left ventricle (LV), as shown on cardiac magnetic resonance (FIGURE 1). Because of a mental disorder, the patient presented poor compliance with anticoagulant (low-molecular-weight heparin [LMWH]) and immunosuppressive treatment since the last hospitalization.

Transthoracic echocardiography on admission showed an extremely large thrombus almost occluding the LV from the mid to apical segments, with an impairment of LV contractility. A comparative cardiac magnetic resonance confirmed thrombus enlargement from 22 × 31 mm to 29 × 44 mm and revealed a more advanced...
endocardial fibrosis (FIGURE 2). Evidence-based therapy was administered with LMWH, azathioprine, and glucocorticoids, and the patient was finally discharged to a nursing home where he received optimal medical treatment to improve his compliance.

Follow-up transthoracic echocardiography at 3 months showed a significant decrease in the thrombus size without complete dissolution; LMWH was switched to acenocumarol dosed according to the recommended therapeutic international normalized ratio range of 2 to 3.

ARTICLE INFORMATION

CONFLICT OF INTEREST None declared.


REFERENCES